Abstracts tagged "Therapy, complementary"

Abstract Number: 0551 • ACR Convergence 2022
Medical Cannabis Use by Rheumatology Patients According to Inflammatory versus Non-Inflammatory Condition
kevin boehnke¹, Tristin Smith¹, Ying He¹, marc martel², david williams¹ and Mary-Ann Fitzcharles³, ¹University of Michigan, Ann Arbor, MI, ²McGill University, Montréal-Ouest, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Persistent pain and poor sleep are common symptoms experienced by patients with rheumatic diseases. Medical cannabis (MC) may offer symptomatic relief and is increasingly…
Abstract Number: 0912 • ACR Convergence 2022
Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis
Kristin Wipfler¹, Joanna Zeiger², Teresa Simon³, Stuart Kassan⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁴Colorado Arthritis Associates, Lakewood, CO, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Fatty acid amide hydrolase (FAAH) is a serine hydrolase that breaks down the endocannabinoid/cannabinoid receptor agonist anandamide. Variants in the FAAH gene have been…
Abstract Number: 0738 • ACR Convergence 2021
Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Weiheng Chen¹, Mengge Song¹, Yan Jia¹, Jigao Sun¹, Yan Zhao², Zhipeng Xue³, Qianglong Chen², xiangrong Zeng² and Chenchen Wang⁴, ¹The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), ²2Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), ³1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), ⁴Tufts Medical Center, Boston, MA
Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
Abstract Number: 0957 • ACR Convergence 2021
Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial
Jill Hahn¹, Nancy Cook², Erik Alexander³, Sonia Friedman³, Vadim Bubes³, Joseph Walter³, Gregory Kotler³, I-Min Lee³, JoAnn Manson³ and Karen Costenbader⁴, ¹Harvard T.H. Chan School of Public Health, Boston, MA, ²Brigham and Womens' Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA
Background/Purpose: In observational studies, vitamin D has been inconsistently associated with reduced risk of several autoimmune diseases, and a large randomized, controlled trial has been…
Abstract Number: 0527 • ACR Convergence 2020
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
Nancy Agmon-Levin¹, Mark Berman², Liora Harel³, Merav Lidar⁴, Soad Hajyahia¹ and Daphna Paran⁵, ¹Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, ⁴Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, ⁵Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…
Abstract Number: 0730 • ACR Convergence 2020
To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Maria Teran¹, Alina Lucica Boteanu², Carlos Guillen¹, Cristina Pijoan¹, Jose Quinones¹, Veronica Garcia³, Ivan Del Bosque-Granero³, Laura Calvo-Sanz⁴ and Mónica Vázquez⁴, ¹Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…
Abstract Number: 0867 • ACR Convergence 2020
Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients
Shivani Garg¹, Tripti Singh¹, Sarah Panzer² and Christie Bartels³, ¹UW Madison, Madison, WI, ²UW-Madison, Madison, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is a pivotal therapy for lupus nephritis (LN) as it contributes to 65% lower mortality and 84% lower renal damage compared to…
Abstract Number: 1068 • ACR Convergence 2020
Efficacy of Early Initiation of Plasma Exchange Therapy for a Patient with Anti-MDA5 Autoantibody-Positive Dermatomyositis Developing Refractory Rapidly Progressive Interstitial Lung Disease
Noriko Sasaki¹, Akira Ishii¹, Keigo Shimura¹, Azusa Kojima¹, Mai Sugiyama², Yuto Izumi¹, Kazuki Hirano¹, Sho Sasaki², Takayoshi Kurabayashi¹, Yuji Hosono², Chiho Yamada² and Shinji Sato², ¹Tokai University School of Medicine, Isehara, Kanagawa, Japan, ²Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Dermatomyositis (DM), and particularly the subtype clinically amyopathic DM (CADM), is often associated with fatal rapidly progressive interstitial lung disease (RP-ILD) when anti-melanoma differentiation-associated…
Abstract Number: 1392 • ACR Convergence 2020
Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Alberto Sulli¹, Sabrina Paolino¹, Giorgia Ferrari¹, Carmen Pizzorni¹, Elvis Hysa¹, Maurizio Cutolo¹ and Emanuele Gotelli¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy
Background/Purpose: Aminaphtone has been used for many years to treat microvascular disorders. In vitro Aminaphtone counteracts vasoconstriction downregulating endothelin-1 production and interferes with adhesion molecules…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].